Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$10.11
▲ $0.11 (+1.1%)
Market data updated: 09/19 11:28 AM
Fundamentals updated: 09/18/2026
News analyzed: 09/19/2026
Market Cap
$1.67B
Day Range
$9.76 - $10.15
52-Week Range
$6.20 - $11.97
Beta
—
Next Earnings
04.11.2026
Support
$7.15
Resistance
$10.75
NVAX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+19.2% (1Y)
Strengths: 20/30 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 64.7%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$19.10 vs. price $10.11 (-288.9%)
Fair Value
Signal tension
Growth scores strong (68/100), but fair-value analysis scores this stock as relatively expensive (43/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
66
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
16d ago · $10.02
Evidence: Euphoria score crossed 55 (now 60)
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
68
Quality
58
Value
43
Momentum
71
Risk
40
Sentiment
98
Fundamental
70
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Novavax has centered on its stock performance and strategic shifts, particularly speculation about its Matrix-M technology—linked to unconfirmed rumors of favorable safety profiles in oncology applications—driving a sharp 30% monthly gain. Investors also highlight the company’s pivot toward licensing deals and cost optimization, alongside broader industry trends in healthcare innovation. No concrete vaccine approvals or major clinical updates were reported.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Novavax, Inc.. News trend score: 98. Reason: 10 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
31
🎯 Conviction (vs. Emotion)
45
Psychology
34
Fundamentals
70
Technical
71
Valuation
43
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The price rise has far outpaced the actual improvement in fundamental data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
+10%
Market Narrative
71
Fundamental Reality
45
Narrative Gap
+26
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
NVAX’s market behavior suggests a dominant FOMO-driven rally, with momentum, volume, and overbought conditions fueling speculative enthusiasm. The narrative-reality gap (25 points) implies optimism exceeds tangible fundamentals, while overconfidence and euphoria further decouple price from earnings growth. Herding remains muted, as the stock underperforms peers slightly. The key question is whether this momentum can sustain itself or if the extreme overbought RSI and Bollinger %B signal an impending pullback.
Updated: 09/09/2026, 06:58 AM
What could change this?
👥 What the crowd believes
"Shares of Novavax are trading higher Monday, extending its 30% monthly gains on **COVID-19 vaccine approvals** and broader biotech strength."
"**Matrix-M Oncology speculation** is driving retail trader interest, despite no confirmed news."
"The move that actually changed the company's business model happened quietly last week and has nothing to do with oncology — **licensing and cost-structure optimization**."
📈 10D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham (Enterprising Investor) — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
NVAX sparks a sharp divide among historical methodologies, with some seeing it as a high-conviction opportunity and others flagging it as a speculative or overvalued bet. Benjamin Graham’s Enterprising Investor framework scores it a near-perfect 100, suggesting a deep statistical discount ripe for aggressive capital deployment, while Peter Lynch’s growth-oriented approach (96) and even Defensive Graham (91) also lean bullish, implying the stock’s price hasn’t yet reflected its potential. Meanwhile, trend-followers like Jesse Livermore (86) and liquidity-focused investors like Walter Bagehot (83) see it as a solid play, reinforcing its appeal to those prioritizing momentum or resilience. However, Fisher (68) and Veblen (65) temper enthusiasm, noting it lacks the exceptional quality or transformative value creation Fisher sought, though Veblen still sees growth aligned with real progress. The split widens further: Marks (52) and Smith (63) caution that expectations may be baked in, while Mackay (47) and Loeb (38) warn of crowd-driven risk and capital-threatening volatility. At the extremes, Nelson (5) and Housel (0) dismiss it outright, viewing it as either overbought or a volatility trap that would test even the most patient investors’ discipline.
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 100
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 40%
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 96
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 91
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 40%
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 83
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 68
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 65
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 63
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 57
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 45
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 45
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 38
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 34
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 33
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 31
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 25
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 279 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (8 bullish · 3 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
93.5%
Operating Margin
40.3%
Net Margin
39.2%
EBITDA Margin
42.8%
ROE
-344.7%
ROA
37.4%
ROIC
—
EPS
$2.72
Cash
$240.63M
Total Debt
—
Current Ratio
2.13
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$10.11
Estimated Fair Value (DCF)
-$19.10
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-288.9%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
-5.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | -5.0% | $-237.69M | $-218.06M |
| 2 | -3.1% | $-230.26M | $-193.80M |
| 3 | -1.2% | $-227.38M | $-175.58M |
| 4 | 0.6% | $-228.80M | $-162.09M |
| 5 | 2.5% | $-234.52M | $-152.42M |
Base FCF (last actual year)
$-250.19M
Terminal Value
$-3.70B
Present Value of Terminal Value
$-2.40B
Enterprise Value
$-3.31B
Net Debt
$0
Equity Value
$-3.31B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
-$0.74
Tangible Book Value per Share (Tangible NAV)
-$1.39
Sentiment based on basic keywords (not AI) — 10 positive, 8 neutral, 2 negative out of the last 20 articles.
Yahoo · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 17.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
StockStory · 12.9.2026
Yahoo · 12.9.2026
Zacks · 11.9.2026
Yahoo · 11.9.2026
Yahoo · 10.9.2026
StockStory · 10.9.2026
Yahoo · 10.9.2026
MarketBeat · 10.9.2026
SeekingAlpha · 10.9.2026
Yahoo · 10.9.2026
MarketBeat · 10.9.2026
SeekingAlpha · 9.9.2026
Novavax, Inc. (NVAX) currently has a StockIQ AI score of 66/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
NVAX currently scores 66/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, NVAX's estimated fair value is -$19.10, which is 288.9% below the current price of $10.11. This is one valuation model among several signals in the fair-value category, not a price target.
NVAX's technical score is 71/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 64.7%; Earnings per share (EPS) growth: 309.8%; Net income growth: 334.8%.
Based on the real signals StockIQ computed: Estimated fair value: -$19.10 vs. price $10.11 (-288.9%); ATR: 5.7% of price; Calmar: 0.14 (3y annualized return 10.5% / max drawdown 74.1%).
StockIQ has no recorded dividend payment history for NVAX.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| DOUGLAS RICHARD | Exercise of Derivative Securities | 20.6.2026 | 18,880 | +18,880 | — |
| MOTT DAVID M | Exercise of Derivative Securities | 20.6.2026 | 18,880 | +18,880 | — |
| King Rachel K. | Exercise of Derivative Securities | 20.6.2026 | 18,880 | +18,880 | — |
| MCGLYNN MARGARET G | Exercise of Derivative Securities | 20.6.2026 | 18,880 | -18,880 | — |
| Alton Gregg H | Exercise of Derivative Securities | 20.6.2026 | 18,880 | -18,880 | — |
| King Rachel K. | Exercise of Derivative Securities | 20.6.2026 | 18,880 | -18,880 | — |
| DOUGLAS RICHARD | Exercise of Derivative Securities | 20.6.2026 | 18,880 | -18,880 | — |
| Rodgers Richard J | Exercise of Derivative Securities | 20.6.2026 | 18,880 | -18,880 | — |
| MCGLYNN MARGARET G | Exercise of Derivative Securities | 20.6.2026 | 18,880 | +18,880 | — |
| MOTT DAVID M | Exercise of Derivative Securities | 20.6.2026 | 18,880 | -18,880 | — |
| Rodgers Richard J | Exercise of Derivative Securities | 20.6.2026 | 18,880 | +18,880 | — |
| Alton Gregg H | Exercise of Derivative Securities | 20.6.2026 | 18,880 | +18,880 | — |
| Alton Gregg H | Exercise of Derivative Securities | 20.6.2026 | 47,685 | +18,880 | — |
| Alton Gregg H | Exercise of Derivative Securities | 20.6.2026 | 0 | -18,880 | — |
| MOTT DAVID M | Exercise of Derivative Securities | 20.6.2026 | 79,770 | +18,880 | — |
| MOTT DAVID M | Exercise of Derivative Securities | 20.6.2026 | 0 | -18,880 | — |
| MCGLYNN MARGARET G | Exercise of Derivative Securities | 20.6.2026 | 44,468 | +18,880 | — |
| MCGLYNN MARGARET G | Exercise of Derivative Securities | 20.6.2026 | 0 | -18,880 | — |
| DOUGLAS RICHARD | Exercise of Derivative Securities | 20.6.2026 | 73,220 | +18,880 | — |
| DOUGLAS RICHARD | Exercise of Derivative Securities | 20.6.2026 | 0 | -18,880 | — |
| King Rachel K. | Exercise of Derivative Securities | 20.6.2026 | 44,070 | +18,880 | — |
| King Rachel K. | Exercise of Derivative Securities | 20.6.2026 | 0 | -18,880 | — |
| Rodgers Richard J | Exercise of Derivative Securities | 20.6.2026 | 47,370 | +18,880 | — |
| Rodgers Richard J | Exercise of Derivative Securities | 20.6.2026 | 0 | -18,880 | — |
| MOTT DAVID M | Grant/Award from Employer | 18.6.2026 | 21,270 | +21,270 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
48,784,134 shares short as of 2026-08-31 · vs. 45,659,491 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
53.9% of trading volume this week was short selling, vs. 51.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology